Recent proteomic analyses determined that high levels of CRABP2 are an adverse prognostic marker in estrogen receptor–negative breast tumors, and another study identified CRABP2 to be a subtype-specific biomarker for ovarian cancer [26]. This evidence concerns the gene ESR1 and ovarian cancer.